viewTiziana Life Sciences PLC

Tiziana Life Sciences to spin off personalised medicine businesses as AccuStem

The proposed spin-off will be put to shareholders for approval

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said the demerger of its StemPrintER unit was progressing to plan. 

Back in May, the biotech company said it was looking to spin off its StemPrintER and SPARE genomics-based personalised medicine businesses into a separate company.

This new company will be called AccuStem. 

READ: Tiziana's diagnostics spinout could be worth $280mln, says Wall Street analyst

Tiziana’s management is currently seeking tax clearances for the proposed spin-off before putting the proposals to shareholders for approval, and said further details will be announced soon.

The London- and New York-listed company added that it has postponed a potential decision on cancellation of the trading of its shares on AIM due to the continuing impact of COVID-19. 

“No final decision on this matter will now be taken until at least Q4 2020,” Tiziana said.

Investment bank JPMorgan will reopen issuances and cancellations of the company's American Depositary Shares on August 4 after effecting a ratio change to the company's sponsored Level I American Depositary Receipt ("ADR") programme.

The former ratio of five ordinary shares to one ADS has been changed to two-to-one and will be effective on July 31 when ADR holders will receive 1.5 additional ADRs for every one ADR held.

Quick facts: Tiziana Life Sciences PLC

Price: 157 GBX

Market: AIM
Market Cap: £303.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

on 09/22/2020

2 min read